Japan ALS Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Japan · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$49.0 MnPlaceholder estimate
Estimate 2025$52.6 Mn5.7% of the global market
Projected 2034$99.2 Mn 88.5%Adds $46.6 Mn over 9 forecast years
CAGR 2025–20347.3%Faster than 34% of 180 Pharmaceuticals markets here
4 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Japan ALS Treatment Market Analysis Executive Summary
ALS treatments aim to slow amyotrophic lateral sclerosis, a disease that destroys nerve cells controlling muscles.
Key segments of the ALS Treatment market include drug (Riluzole, Edaravone and Tofersen) and route (Oral, Intravenous and Intrathecal).
Japan ALS Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Japan ALS Treatment Market Dynamics
Market Growth Drivers
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the ALS Treatment market.
Opportunity
Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the ALS Treatment market strong room to grow.
Market Restraints
Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the ALS Treatment market.
Competitive Landscape for ALS Treatment Market in Japan
The ALS Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for ALS Treatment Market in Japan
ALS Treatment in Japan: rules, payment and research
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).[2] ClinicalTrials.gov lists 4 studies on ALS Treatment that are recruiting, active or about to start in Japan.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for ALS Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in ALS Treatment right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
ALS Treatment in context
Japan compared
Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
Placeholder estimate: about $52.6 Mn in 2025, rising to about $99.2 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the ALS Treatment market in Japan growing?
Placeholder estimate: about 7.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the ALS Treatment market report cover?
The report splits the market by drug (Riluzole, Edaravone, Tofersen, Others), route (Oral, Intravenous, Intrathecal) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the ALS Treatment market?
Key players include Biogen Inc, Mitsubishi Tanabe Pharma Corporation, Amylyx Pharmaceuticals, Sanofi and Cytokinetics.
What is driving the ALS Treatment market?
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the ALS Treatment market.
Who regulates ALS Treatment in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on ALS Treatment are running in Japan?
4 studies are recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
How much research is published on ALS Treatment?
PubMed lists 138 papers on ALS Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Japan 
China
India
US
Canada
Germany
France
UK
Brazil
Ecuador
Italy
Saudi Arabia
Spain
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
Eli Lilly and Company
Glenmark Pharmaceuticals